JP2022520998A5 - - Google Patents

Info

Publication number
JP2022520998A5
JP2022520998A5 JP2021549227A JP2021549227A JP2022520998A5 JP 2022520998 A5 JP2022520998 A5 JP 2022520998A5 JP 2021549227 A JP2021549227 A JP 2021549227A JP 2021549227 A JP2021549227 A JP 2021549227A JP 2022520998 A5 JP2022520998 A5 JP 2022520998A5
Authority
JP
Japan
Application number
JP2021549227A
Other languages
Japanese (ja)
Other versions
JPWO2020172528A5 (https=
JP2022520998A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/019215 external-priority patent/WO2020172528A1/en
Publication of JP2022520998A publication Critical patent/JP2022520998A/ja
Publication of JP2022520998A5 publication Critical patent/JP2022520998A5/ja
Publication of JPWO2020172528A5 publication Critical patent/JPWO2020172528A5/ja
Pending legal-status Critical Current

Links

JP2021549227A 2019-02-22 2020-02-21 アルブミン結合抗体及びその使用 Pending JP2022520998A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962809475P 2019-02-22 2019-02-22
US62/809,475 2019-02-22
PCT/US2020/019215 WO2020172528A1 (en) 2019-02-22 2020-02-21 Albumin binding antibodies and use thereof

Publications (3)

Publication Number Publication Date
JP2022520998A JP2022520998A (ja) 2022-04-04
JP2022520998A5 true JP2022520998A5 (https=) 2023-02-28
JPWO2020172528A5 JPWO2020172528A5 (https=) 2023-02-28

Family

ID=72144485

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021549227A Pending JP2022520998A (ja) 2019-02-22 2020-02-21 アルブミン結合抗体及びその使用

Country Status (6)

Country Link
US (1) US12479909B2 (https=)
EP (1) EP3927740A4 (https=)
JP (1) JP2022520998A (https=)
CN (1) CN113508134B (https=)
TW (1) TW202045545A (https=)
WO (1) WO2020172528A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
EP3806889A4 (en) * 2018-06-18 2022-07-13 Anwita Biosciences, Inc. CYTOKI FUSION PROTEINS AND USES THEREOF
TW202128961A (zh) 2019-11-20 2021-08-01 美商安維塔生物科學股份有限公司 細胞激素融合蛋白及其醫藥組合物及治療應用
US11897930B2 (en) 2020-04-28 2024-02-13 Anwita Biosciences, Inc. Interleukin-2 polypeptides and fusion proteins thereof, and their pharmaceutical compositions and therapeutic applications
EP4171611A4 (en) 2020-07-30 2024-10-02 Anwita Biosciences, Inc. Interleukin-22 fusion proteins, and their pharmaceutical compositions and therapeutic applications
CN116419973A (zh) * 2020-10-02 2023-07-11 新加坡科技研究局 用于蛋白质生产和筛选的表达系统
JP2023549537A (ja) * 2020-11-16 2023-11-27 エイビー セラピューティクス インコーポレイテッド 多重特異性抗体およびその使用方法
CN117042788A (zh) * 2020-12-08 2023-11-10 佳努克斯治疗公司 半衰期延长组合物和方法
CN117545504A (zh) * 2021-06-07 2024-02-09 上海济煜医药科技有限公司 抗人血清白蛋白的抗原结合蛋白
JP2025517120A (ja) * 2022-05-05 2025-06-03 インヒブルクス バイオサイエンシズ インコーポレイテッド アルブミン結合ポリペプチド及びその使用
EP4573119A1 (en) * 2022-08-17 2025-06-25 Institut National de la Santé et de la Recherche Médicale Improved anti-albumin nanobodies and their uses
WO2024051796A1 (en) * 2022-09-09 2024-03-14 Wuxi Biologics (Shanghai) Co., Ltd. Albumin binding proteins, fusion proteins and uses thereof
WO2024097639A1 (en) * 2022-10-31 2024-05-10 Modernatx, Inc. Hsa-binding antibodies and binding proteins and uses thereof
JP2026506075A (ja) 2023-02-17 2026-02-20 アブリンクス エン.ヴェー. 新生児型fc受容体に結合するポリペプチド
WO2024236068A1 (en) * 2023-05-17 2024-11-21 Navigo Proteins Affinity ligand for a single chain antibody fragment specific for serum albumin
NL2036011B1 (en) 2023-10-12 2025-04-30 Synapse Res Institute Molecules for reversing anti-coagulant activity of direct oral anticoagulants

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004041867A2 (en) 2002-11-08 2004-05-21 Ablynx N.V. Camelidae antibodies against imminoglobulin e and use thereof for the treatment of allergic disorders
EP2102244A2 (en) 2006-12-19 2009-09-23 Ablynx N.V. Amino acid sequences directed against a metalloproteinase from the adam family and polypeptides comprising the same for the treatment of adam-related diseases and disorders
EP2692736B1 (en) 2008-10-14 2018-04-18 National Research Council Of Canada Bsa-specific antibodies
JP2012532620A (ja) 2009-07-16 2012-12-20 グラクソ グループ リミテッド 改良型抗血清アルブミン結合単一可変ドメイン
US9556273B2 (en) * 2010-03-29 2017-01-31 Vib Vzw Anti-macrophage mannose receptor single variable domains for targeting and in vivo imaging of tumor-associated macrophages
JP2013537421A (ja) * 2010-08-20 2013-10-03 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド 改良された抗血清アルブミン結合変異体
AU2013201422B2 (en) * 2012-01-23 2015-04-09 Ablynx Nv Sequences directed against hepatocyte growth factor (HFG) and polypeptides comprising the same for the treatment of cancers and/or tumors
BR112014020694A2 (pt) * 2012-02-15 2018-05-08 Amunix Operating Inc. proteína de fusão do fator viii compreendendo polipeptídeo do fator viii fusionado a polipeptí-deo recombinante estendido (xten) e seu método de fabricação, ácido nucleico, vetores, célula hospedeira, bem como composição farmacêutica e seu uso no tratamento de coagulopatia, episódio de hemorragia e hemofilia a
WO2016034968A1 (en) 2014-09-02 2016-03-10 Pfizer Inc. Therapeutic antibody
WO2016081639A1 (en) 2014-11-19 2016-05-26 Genentech, Inc. Antibodies against bace1 and use thereof for neural disease immunotherapy
EA201792573A1 (ru) * 2015-05-21 2018-04-30 Харпун Терапьютикс, Инк. Триспецифические связанные белки и способы их применения
CN115925919A (zh) * 2015-11-13 2023-04-07 埃博灵克斯股份有限公司 改进的血清白蛋白结合免疫球蛋白可变结构域
JP7101621B2 (ja) * 2016-05-20 2022-07-15 ハープーン セラピューティクス,インク. 単一ドメイン血清アルブミン結合タンパク質
RU2022101604A (ru) * 2016-12-07 2022-03-29 Аблинкс Нв Улучшенные отдельные вариабельные домены иммуноглобулина, связывающиеся с сывороточным альбумином
AU2018265856B2 (en) 2017-05-12 2023-04-27 Harpoon Therapeutics, Inc. Mesothelin binding proteins
DK3661954T3 (da) * 2017-08-03 2022-04-19 Amgen Inc Interleukin-21-muteiner og fremgangsmåder til behandling
CA3076250A1 (en) * 2017-10-02 2019-04-11 Vib Vzw Compounds to inhibit bacterial s-layer protein assembly
EP3806889A4 (en) 2018-06-18 2022-07-13 Anwita Biosciences, Inc. CYTOKI FUSION PROTEINS AND USES THEREOF
TW202128961A (zh) * 2019-11-20 2021-08-01 美商安維塔生物科學股份有限公司 細胞激素融合蛋白及其醫藥組合物及治療應用
EP4171611A4 (en) * 2020-07-30 2024-10-02 Anwita Biosciences, Inc. Interleukin-22 fusion proteins, and their pharmaceutical compositions and therapeutic applications

Similar Documents

Publication Publication Date Title
BR112023005462A2 (https=)
BR112023012656A2 (https=)
BR112021014123A2 (https=)
BR112023009656A2 (https=)
BR112022009896A2 (https=)
JP2023552462A5 (https=)
BR112021017747A2 (https=)
BR112022024743A2 (https=)
BR112022026905A2 (https=)
BR112023011738A2 (https=)
BR112023004146A2 (https=)
BR102021018859A2 (https=)
BR102021015500A2 (https=)
BR102021007058A2 (https=)
BR102020022030A2 (https=)
BR112023016292A2 (https=)
BR112023011610A2 (https=)
BR112023011539A2 (https=)
BR112023008976A2 (https=)
BR102021020147A2 (https=)
BR102021018926A2 (https=)
BR102021018167A2 (https=)
BR102021017576A2 (https=)
BR102021016837A2 (https=)
BR102021016551A2 (https=)